

Corporate Overview

Telesis Bio | Q1 2026

Safe Harbor Statement

The information contained in this presentation has been made available to you with the consent of Telesis Bio Inc. (“Telesis Bio,” the “Company,” “we” or “our”) for informational purposes only. This presentation is strictly confidential and may not be reproduced or redistributed in whole or in part nor may its contents be disclosed to any other person without our prior written permission. By viewing this presentation, you agree to keep any information (including oral information) that we provide as part of the presentation confidential and not to disclose any of the information to any other person without such permission.

This presentation contains forward-looking statements. All statements contained in this presentation other than statements of historical facts, including our business strategy and plans and objectives for future operations, including our financial performance, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “designed to,” “will” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Forward-looking statements made in this presentation include statements about estimates of the synthetic biology market, market growth, and new market expansion; our future revenue, expenses, capital requirements and our needs for additional financing; our expectations regarding the rate and degree of market acceptance of our BioXp system, BioXp kits and benchtop reagents; the ability of our products to facilitate the design-build-test paradigm of synthetic biology; and the size and growth of the synthetic biology market and competitive companies and technologies and our industry, and many others. Forward-looking statements are subject to a number of risks and uncertainties and represent our views as of the date of the presentation. The future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We describe these and other risks and uncertainties in our filings with the Securities and Exchange Commission (“SEC”), which are available on the SEC website. You should not rely on these statements as representing our views in the future. The forward-looking statements contained in this presentation speak only as of the date of this presentations and we undertake no obligation or duty to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation is not an offer to sell securities of Telesis Bio and it is not soliciting offers to buy securities of Telesis Bio in any jurisdiction where the offer or sale is not permitted.

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We believe that these third-party sources and estimates are reliable, but have not independently verified them. Our estimates of the potential market opportunities for our products include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by us.

Trademarks in this presentation are the property of their respective owners and used for informational and education purposes only.



Unlocking the power of on-demand biology to transform therapeutic development

Gibson SOLA for overnight synthetic biology

Leadership Team of Domain Experts



Eric Esser
President & CEO



Rocky McDonald
Senior VP, Finance



Daniel Gibson
Chief Technology Officer




Krishna Kannan
VP, Product and Operations



Telesis Bio Is Built on a History of Innovation in Molecular Biology



Original IP from JCVI



Digital to Biological Conversion



Gibson Short Oligonucleotide Ligation Assembly (SOLA)



Gibson Assembly




Telesis Bio Established




330+

patents in Telesis patent portfolio



Digital to biological converter

Distributed Synthesis Eliminates Constraints on Therapeutic Discovery and Development



Shrink Timelines

No more waiting for external supply, iterate way faster



Control Quality

Stop worrying about variable purity and fidelity



Break Free from Limits

Gain the freedom to explore novel domains without the need for specialist third parties




Control Your IP

Keep your proprietary data to yourself, feed your own AI instead of giving it to others


Gibson SOLA On-Demand Synthesis Supercharges Productivity

Comprehensive and flexible reagent and software solution for in-lab synthesis to accelerate discovery


- Unlock the power of overnight synthesis of DNA, mRNA and protein
- Extreme quality, high reliability, and fully automated on your platform of choice
- Complex design options to power therapeutic discovery
- Rich data stays in-house to advance AI/ML discovery pipelines



Our Gibson SOLA Reagent and Software Platform



Block approach




Assembly



Reagent Kits

Simple and flexible chemistry for synthesis

- ✓ Easy to scale with standard liquid handling automation
- ✓ Amenable to very high throughput applications
- ✓ Simple, reliable, and fast ligation approach enables very long constructs with extreme fidelity and purity
- ✓ Comprehensive and flexible software solution enables high complexity and ease of use




Advanced Software

Algorithms that enable efficient and reliable synthesis, deployable

Gibson SOLA is a Scalable Fully Enzymatic Process

Fixed building blocks and four reaction steps reliably produce extremely high-fidelity DNA



Highly amenable to automation at any scale

How we're delivering Gibson SOLA to the market

Gibson SOLA Discovery

SOLA-Enabled BioXp




Accelerated,
SOLA-quality

Gibson SOLA Beckman



High-throughput
(~30kb/day), turnkey

Gibson SOLA Integrated



> 100kb/day,
integrated, custom

License and
implementation revenue

Durable recurring reagent
revenue

Gibson SOLA Clinical



Selected by 4 Applicants



Future Development

Collaboration

Commercial deliveries of Gibson SOLA Discovery Underway

Building enthusiasm and making good progress in the early innings

Gibson SOLA Discovery in 2025

- Commercially ready
- Fully automated and running at Telesis Bio
- Six licensees across three Gibson SOLA Discovery categories

REGENERON

- Strong pipeline coming into 2026



Strong growth and large durable recurring revenue

Gibson SOLA Clinical Enables Precision Therapeutics


Personalized therapies require fast and distributed manufacturing of patient-specific drugs

Individualized therapeutics are coming

- Large investment underway
- mRNA individualized neoantigen therapies for cancer show promise
- Rapid advancements in diagnostics and AI design
- **ARPA-H GIVE** – Genetic Individualized Medicines for Everyone

Distributed synthesis is required, the pieces are in place

- **Every drug is custom**, speed → outcomes



Gibson SOLA is ideal for distributed manufacturing

- Extreme quality cell-free enzymatic synthesis
- Simple and reliable chemistry
- **Easily integrated** into many formats
- Fast, high-throughput, amenable to miniaturization

First mover owns the “last mile” to the patient





- Owning this channel confers huge **advantage** for both therapeutics and platform licensing

Telesis Bio is investing in this vision, and seeking strategic partnerships for this effort

SOLA is the best platform for integrated on-demand synthesis

Simple enzymatic process makes miniaturization feasible



High Quality

- High-fidelity synthesis**
Built-in error suppression for high quality DNA
- Long shelf life**
Enzymes and oligos can be lyophilized
- Parallelism by design**
Droplets enable high-density replication
- Intelligent, software-driven synthesis**
Logic, not new chemistry, drives efficiencies


- Finite, reusable parts library**
Reusable building blocks, simple cartridge kit
- All aqueous enzymology**
Chip friendly, No harsh chemicals
- Parts-based assembly**
Shortened cycles, fewer steps to miniaturize
- Simple operation**
Dispense->merge->split->incubate

Easy to Integrate


Innovating Solutions to Rapidly Advance Therapeutic and Diagnostic Development



**Gibson SOLA - Groundbreaking
next-gen technology**




**Meeting market needs –
overnight results,
complexity, control**



**Experienced team with
market expertise**



**Targeting high value
applications**



**Nimble company focused
on efficiency and value**

Thank You

CONTACT

Rocky McDonald, Senior VP of
Finance

Rocky.McDonald@telesisbio.com
(619) 518-9270

TelesisBio 

